Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

BACKGROUND: We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env, gag, pol, nef, and tat genes. Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective w...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasan, Sandhya, Schlesinger, Sarah J., Huang, Yaoxing, Hurley, Arlene, Lombardo, Angela, Chen, Zhiwei, Than, Soe, Adesanya, Phumla, Bunce, Catherine, Boaz, Mark, Boyle, Rosanne, Sayeed, Eddy, Clark, Lorna, Dugin, Daniel, Schmidt, Claudia, Song, Yang, Seamons, Laura, Dally, Len, Ho, Martin, Smith, Carol, Markowitz, Martin, Cox, Josephine, Gill, Dilbinder K., Gilmour, Jill, Keefer, Michael C., Fast, Patricia, Ho, David D.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799527/
https://www.ncbi.nlm.nih.gov/pubmed/20111582
http://dx.doi.org/10.1371/journal.pone.0008617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799527/
https://www.ncbi.nlm.nih.gov/pubmed/20111582
http://dx.doi.org/10.1371/journal.pone.0008617

Ejemplares similares